Fierce Pharma

JANUARY 18, 2024

Six months after England’s National Institute for Health and Care Excellence (NICE) spurned Pfizer’s breast cancer treatment Talzenna (talazoparib) because it was not cost effective, the agency has | Six months after England’s National Institute for Health and Care Excellence spurned Pfizer’s breast cancer treatment Talzenna because it was not cost effective, the agency has reversed course following the company’s offer to slash the price.

270

270

European Pharmaceutical Review

JANUARY 18, 2024

An attractive destination for ATMP clinical trials Based on the Cell and Gene Therapy Catapult (CGT Catapult)’s recently published UK 2023 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database , the UK is an attractive location for ATMP clinical trials. This is largely due to the number of ongoing ATMP clinical trials in the UK remaining “largely stable” over the past three years.

Distribution 111

Distribution Manufacturing Medicine Government 111

Fierce Pharma

JANUARY 18, 2024

In its efforts to probe high U.S. drug prices, the Senate health committee has already heard from the heads of Moderna, Eli Lilly, Novo Nordisk and Sanofi. | The Senate Committee on Health, Education, Labor, and Pensions will vote on issuing subpoenas at the end of the month after the Johnson & Johnson and Merck CEOs refused to testify at an upcoming hearing.

Education 265

Education 265

Pharmaceutical Commerce

JANUARY 18, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Management 105

Management Pharma Sales Patients 105

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JANUARY 18, 2024

It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. | It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. On Thursday, the companies revealed their long-awaited merger, with Sun of Mumbai, India, agreeing to purchase outstanding shares in the Israeli drugmaker for $43 each. The deal nets out to $348 million for a 48% premium on Taro's share price of $29.

Pharmaceutical 227

Pharmaceutical 227

MedCity News

JANUARY 18, 2024

BridgeBio will receive $500 million in exchange for royalties from sales of acoramidis, a drug currently under FDA review for treating heart complications caused by the rare disease transthyretin amyloidosis. The deal also refinances lending agreements, providing BridgeBio with access to additional capital.

FDA 111

FDA Sales Biopharma Pharma 111

MedCity News

JANUARY 18, 2024

During a panel discussion at CES 2024, health executives shared safe ways AI can be used to support value-based care. This includes automating tasks and predicting who needs additional care.

Medical 111

Medical 111

Fierce Pharma

JANUARY 18, 2024

Novartis hopes new data will open a $1 billion market opportunity for its radioligand therapy, Lutathera, as a first-line treatment. | Novartis hopes new data will open a $1 billion market opportunity for its radioligand therapy, Lutathera, as a first-line treatment. Friday, the company's ambition received a boost from the phase 3 readout of the NETTER-2 trial.

Marketing 167

Marketing 167

MedCity News

JANUARY 18, 2024

CEO Bill Anderson said despite prior cost-cutting measures, Bayer still has too many layers of management and bureaucracy. A new restructuring will come with layoffs but the corporate shakeup plan does not yet include a separation of Bayer’s business units.

Management 109

Management Government Biopharma Pharma 109

Fierce Pharma

JANUARY 18, 2024

At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. | At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023.

Specialization 130

Specialization Pharma 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

JANUARY 18, 2024

This year’s digital health fundraising environment requires startups to focus more on their unit economics and pathway to profitability, according to Ian Wijaya, managing director at Lazard. He predicted that the ability to achieve profitability will be much more important in 2024 than it has been in the past four years or so.

Management 109

Management 109

Fierce Pharma

JANUARY 18, 2024

AstraZeneca charts new course for Imfinzi in liver cancer, but FDA path remains uncertain aliu Thu, 01/18/2024 - 14:27

FDA 144

FDA 144

pharmaphorum

JANUARY 18, 2024

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.

105

105

European Pharmaceutical Review

JANUARY 18, 2024

The treatment markets for two key diseases areas: insomnia and the rare metabolic disorder, Gaucher disease, are predicted to flourish in the seven major markets (7MM – France, Germany, Italy, Spain, UK, US, and Israel) in 2032, data and analytics company GlobalData suggests. Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia mar

Marketing 98

Marketing Sales Pharmacology Pharma 98

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

JANUARY 18, 2024

Medtech company DermaSensor gets FDA approval for a handheld device, powered by AI, that can be used to detect skin cancer at the point of care

FDA 113

FDA 113

European Pharmaceutical Review

JANUARY 18, 2024

US researchers have reported promising outcomes from a Phase I/II trial in cancer patients treated with cord blood-derived CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell therapy. Published in Nature Medicine , the findings revealed an overall response (OR) rate of 48.6 percent at 100 days post treatment. The one-year progression-free survival (PFS) and overall survival (OS) rates were reported to be 32 percent and 68 percent, respectively, in patients with relapsed or re

Manufacturing 97

Manufacturing Patients Safety Medicine 97

pharmaphorum

JANUARY 18, 2024

AI-powered patient risk assessment company C2-Ai and the Sickle Cell Society have won an NHS contest to find solutions that can tackle health inequality

Healthcare 107

Healthcare Healthcare Patients 107

MedCity News

JANUARY 18, 2024

Telehealth is poised to serve as an essential tool to fill an exploding demand for care. Providers and digital health companies need to act now by expanding telehealth offerings that include on-demand care teams knowledgeable and experienced in GLP-1 drugs, but also overall health and wellness strategies.

Biopharma 100

Biopharma 100

Advertisement

pharmaphorum

JANUARY 18, 2024

India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.

Pharma 96

Pharma Pharmaceutical 96

MedCity News

JANUARY 18, 2024

Increasing innovation in, and consumer demand for, healthcare technology continue to transform the Medtech industry, including in digital health, wearables, diagnostics, telemedicine and other health IT solutions.

Healthcare 99

Healthcare Healthcare 99

Pharmaceutical Technology

JANUARY 18, 2024

The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.

Safety 85

Safety Patients 85

MedCity News

JANUARY 18, 2024

TBD Health is moving into the B2B healthcare space by partnering with digital health companies, starting with FOLX Health and Wisp.

Healthcare 101

Healthcare Healthcare 101

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

pharmaphorum

JANUARY 18, 2024

Bayer has reached a deal with union representatives that will result in a sizeable reduction in managerial roles

Management 82

Management 82

PharmaTimes

JANUARY 18, 2024

Green light concerns generalised myasthenia gravis therapy

101

101

PharmExec

JANUARY 18, 2024

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Patients 52

Patients 52

PharmaVoice

JANUARY 18, 2024

Creative thinking is the name of the game as biopharmas seek to overcome a host of challenges — and investing with purpose, building trust and embracing tech could get them there.

Biopharma 52

Biopharma 52

Advertisement

Distribution

PharmExec

JANUARY 18, 2024

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Management 52

Management Pharma Sales Patients 52

Pharmaceutical Commerce

JANUARY 18, 2024

Data show daily oral dosing of NX-5948 in patients with relapsed or refractory B-cell malignancies experienced a clinical benefit across dose ranges from 50 mg to 200 mg.

FDA 52

FDA Patients 52

PharmaTimes

JANUARY 18, 2024

Company is focused on endocannabinoid system treatments

89

89

Pharmaceutical Commerce

JANUARY 18, 2024

Pivmecillinam (Pivya) has a clinical cure rate of 95% in uncomplicated urinary tract infections and is recommended as a first-line option for treatment in many countries.

FDA 52

FDA 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales